BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28482719)

  • 1. MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.
    Colomer-Lahiguera S; Pisecker M; König M; Nebral K; Pickl WF; Kauer MO; Haas OA; Ullmann R; Attarbaschi A; Dworzak MN; Strehl S
    Leuk Lymphoma; 2017 Dec; 58(12):2895-2904. PubMed ID: 28482719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors.
    Zuurbier L; Gutierrez A; Mullighan CG; Canté-Barrett K; Gevaert AO; de Rooi J; Li Y; Smits WK; Buijs-Gladdines JG; Sonneveld E; Look AT; Horstmann M; Pieters R; Meijerink JP
    Haematologica; 2014 Jan; 99(1):94-102. PubMed ID: 23975177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?
    Kawashima-Goto S; Imamura T; Tomoyasu C; Yano M; Yoshida H; Fujiki A; Tamura S; Osone S; Ishida H; Morimoto A; Kuroda H; Hosoi H
    PLoS One; 2015; 10(7):e0132926. PubMed ID: 26172269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.
    Homminga I; Pieters R; Langerak AW; de Rooi JJ; Stubbs A; Verstegen M; Vuerhard M; Buijs-Gladdines J; Kooi C; Klous P; van Vlierberghe P; Ferrando AA; Cayuela JM; Verhaaf B; Beverloo HB; Horstmann M; de Haas V; Wiekmeijer AS; Pike-Overzet K; Staal FJ; de Laat W; Soulier J; Sigaux F; Meijerink JP
    Cancer Cell; 2011 Apr; 19(4):484-97. PubMed ID: 21481790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia.
    La Starza R; Barba G; Demeyer S; Pierini V; Di Giacomo D; Gianfelici V; Schwab C; Matteucci C; Vicente C; Cools J; Messina M; Crescenzi B; Chiaretti S; Foà R; Basso G; Harrison CJ; Mecucci C
    Haematologica; 2016 Aug; 101(8):951-8. PubMed ID: 27151989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copy Number Alterations in CDKN2A/2B and MTAP Genes Are Associated With Low MEF2C Expression in T-cell Acute Lymphoblastic Leukemia.
    Kumari S; Singh J; Arora M; Ali MS; Pandey AK; Benjamin M; Palanichamy JK; Bakhshi S; Qamar I; Chopra A
    Cureus; 2022 Dec; 14(12):e32151. PubMed ID: 36601176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.
    Bardelli V; Arniani S; Pierini V; Di Giacomo D; Pierini T; Gorello P; Mecucci C; La Starza R
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
    Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
    Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-resolution genomic profiling of pediatric lymphoblastic lymphomas reveals subtle differences with pediatric acute lymphoblastic leukemias in the B-lineage.
    Schraders M; van Reijmersdal SV; Kamping EJ; van Krieken JH; van Kessel AG; Groenen PJ; Hoogerbrugge PM; Kuiper RP
    Cancer Genet Cytogenet; 2009 May; 191(1):27-33. PubMed ID: 19389505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma.
    Xu X; Paxton CN; Hayashi RJ; Dunsmore KP; Winter SS; Hunger SP; Winick NJ; Carroll WL; Loh ML; Devidas M; Gross TG; Bollard CM; Perkins SL; Miles RR
    Blood Adv; 2021 Jul; 5(14):2890-2900. PubMed ID: 34297047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL.
    Chopra A; Bakhshi S; Pramanik SK; Pandey RM; Singh S; Gajendra S; Gogia A; Chandramohan J; Sharma A; Kumar L; Seth R; Rai S; Kumar R
    Eur J Haematol; 2014 Mar; 92(3):211-8. PubMed ID: 24329989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characteristics of
    Ohki K; Kiyokawa N; Saito Y; Hirabayashi S; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fukushima K; Hasegawa D; Fukushima H; Imai M; Kajiwara R; Koike T; Komori I; Matsui A; Mori M; Moriwaki K; Noguchi Y; Park MJ; Ueda T; Yamamoto S; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Takahashi H; Fukushima T; Hayashi Y; Koh K; Manabe A; Ohara A;
    Haematologica; 2019 Jan; 104(1):128-137. PubMed ID: 30171027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB.
    Cordas Dos Santos DM; Eilers J; Sosa Vizcaino A; Orlova E; Zimmermann M; Stanulla M; Schrappe M; Börner K; Grimm D; Muckenthaler MU; Kulozik AE; Kunz JB
    BMC Cancer; 2018 Jun; 18(1):663. PubMed ID: 29914415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
    Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Kentsis A; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
    J Hematol Oncol; 2015 Oct; 8():115. PubMed ID: 26487643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia.
    Wang HP; Zhou YL; Huang X; Zhang Y; Qian JJ; Li JH; Li XY; Li CY; Lou YJ; Mai WY; Meng HT; Yu WJ; Tong HY; Jin J; Zhu HH
    Am J Hematol; 2021 Mar; 96(3):312-319. PubMed ID: 33306218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response.
    Remke M; Pfister S; Kox C; Toedt G; Becker N; Benner A; Werft W; Breit S; Liu S; Engel F; Wittmann A; Zimmermann M; Stanulla M; Schrappe M; Ludwig WD; Bartram CR; Radlwimmer B; Muckenthaler MU; Lichter P; Kulozik AE
    Blood; 2009 Jul; 114(5):1053-62. PubMed ID: 19406988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
    Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
    Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation and copy number variation profiling of T-cell lymphoblastic leukemia and lymphoma.
    Haider Z; Landfors M; Golovleva I; Erlanson M; Schmiegelow K; Flægstad T; Kanerva J; Norén-Nyström U; Hultdin M; Degerman S
    Blood Cancer J; 2020 Apr; 10(4):45. PubMed ID: 32345961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
    Khogeer H; Rahman H; Jain N; Angelova EA; Yang H; Quesada A; Ok CY; Sui D; Wei P; Al Fattani A; Pierce S; Loghavi S; Lamb A; Hu P; Thakral B; Kanagal-Shamanna R; Jorgensen JL; Jabbour EJ; Kantarjian HM; Medeiros LJ; Khoury JD
    Br J Haematol; 2019 Aug; 186(4):538-548. PubMed ID: 31115909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.
    Bond J; Marchand T; Touzart A; Cieslak A; Trinquand A; Sutton L; Radford-Weiss I; Lhermitte L; Spicuglia S; Dombret H; Macintyre E; Ifrah N; Hamel JF; Asnafi V
    Haematologica; 2016 Jun; 101(6):732-40. PubMed ID: 26944475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.